Merck Foundation Chairman and CEO Meet Nigeria First Lady to Underscore Their Long-Term Commitment to Transform Patient Care Landscape in the Country
Senator Dr. Rasha Kelej expressed, 'It was a privilege to meet my dear sister H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria and officially appoint her to be the Ambassador of 'Merck Foundation More Than a Mother'. During our meeting, we discussed the beginning of our long-term partnership and underscored our commitment towards building healthcare capacity and transforming patient care landscape by providing scholarships for local Nigerian doctors in 42 critical and underserved specialties. We also discussed about addressing critical social and health issues in the country including breaking the infertility stigma and supporting girl education.'
'It gives me great pleasure to share that till today, 63 scholarships have been provided for doctors in Nigeria and affirm our commitment towards enhancing healthcare delivery by providing scholarships for local doctors in Nigeria,' Dr. Rasha Kelej added.
H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria and Ambassador of 'Merck Foundation More Than a Mother' expressed, 'It is a pleasure to welcome and meet the Chairman and CEO of Merck Foundation in our country. I am truly pleased to learn about their impactful and highly beneficial programs, particularly Educating Linda program to support girl education and scholarship program for advancing healthcare capacity. It is encouraging to know that Merck Foundation has provided 63 scholarships to our local doctors in critical medical specialties. I am fully committed to scaling up all their programs to benefit our people.'
Prof. Dr. Frank Stangenberg Haverkamp, Chairman of Merck Foundation BOT shared, 'It was a great pleasure to meet H.E. Senator OLUREMI TINUBU, CON, The First Lady of the Federal Republic of Nigeria, and to reinforce our shared commitment to advancing healthcare capacity in Nigeria and across Africa.
Our aim is to improve the overall health and wellbeing of people by building healthcare capacity across Africa, Asia and other developing countries. We are strongly committed to transforming patientcare landscape through our scholarships program. Till today, we have provided more than 2270 scholarships for young doctors from 53 countries in 44 critical and underserved specialties.'
Merck Foundation has provided 63 scholarships for Nigerian doctors, out of which 8 scholarships have been provided for Fertility, Embryology, Sexual & Reproductive Medicine, Biotechnology of Human Assisted Reproduction and Embryology and Women's Health.
Moreover, 38 scholarships have been provided for Diabetes, Preventative Cardiovascular Medicine, Cardiology, Endocrinology and Obesity & Weight Management. After completion of the course, these doctors will be able to establish diabetes or hypertension clinics in their Health Centre or Hospital with the aim to help prevent and manage the disease in their own communities.
Additionally, 17 scholarships have been provided for other critical and underserved specialties like Oncology Research, Clinical Psychiatry, Dermatology in Clinical Practice, Pain Management, Respiratory Medicine, Care of the Older Person, Critical Care, Rheumatology, and more.
Moreover, As a part of their 'Educating Linda' program, Merck Foundation has also sponsored the education of 20 high performing but underprivileged Nigerian schoolgirls.
Merck Foundation has also conducted three edition of Online Health Media Training for the Nigerian journalists, to emphasize on the important role that media plays to influence society to create a cultural shift with the aim to address wide range of social and health issues such as: Breaking Infertility Stigma, Supporting Girl Education, Women Empowerment, Ending Child Marriage, Ending FGM, and/ or Stopping GBV at all levels; to underscore the importance of Empowering Girls and Women in Education and to understand the social and psychological impact of infertility stigma and other social issues like GBV, Child Marriage, FGM etc. over women and their families and communities.
Moreover, to raise awareness of early detection and prevention of Diabetes and Hypertension.
Merck Foundation in partnership with The First Lady of Nigeria has also launched their 8 important Merck Foundation Awards for Media, Musicians & Singers, Fashion Designers, Filmmakers, and students & new potential talents in these fields.
'I invite the young Nigerian talents to share their creative and inspiring work with us. We have celebrated many winners from Nigeria in the previous years and look forward to celebrating winners this year too,' concluded Senator Dr. Kelej.
Details of the Awards:
Merck Foundation Media Recognition Awards 'More Than a Mother' 2025: Media representatives and media students are invited to showcase their work to raise awareness about one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30th September 2025. Merck Foundation Fashion Awards 'More Than a Mother' 2025: All Fashion Students and Designers are invited to create and share designs to deliver strong and influential messages to raise awareness about one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30th September 2025. Merck Foundation Film Awards 'More Than a Mother' 2025: All Filmmakers, Students of Film Making Training Institutions, or Young Talents of Africa are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to address one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30th September 2025. Merck Foundation Song Awards 'More Than a Mother' 2025: All Singers and Musical Artists are invited to create and share a SONG with the aim to address one or more of the following social issues: Breaking Infertility Stigma and Women Empowerment. Submission deadline: 30th September 2025. Merck Foundation Media Recognition Awards 'Diabetes & Hypertension' 2025: Media representatives are invited to showcase their work through strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension.
Submission deadline: 30th October 2025.
Merck Foundation Fashion Awards 'Diabetes & Hypertension' 2025: All Fashion Students and Designers are invited to create and share designs to deliver strong and influential messages to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension.
Submission deadline: 30th October 2025.
Merck Foundation Film Awards 'Diabetes & Hypertension' 2025: All Filmmakers, Students of Film Making Training Institutions, or Young Talents of Africa are invited to create and share a long or short FILMS, either drama, documentary, or docudrama to deliver strong and influential messages to promote a healthy lifestyle, raise awareness about prevention and early detection of Diabetes and Hypertension.
Submission deadline: 30th October 2025.
Merck Foundation Song Awards 'Diabetes & Hypertension' 2025: All Singers and Musical Artists are invited to create and share a SONG with the aim to promote a healthy lifestyle and raise awareness about the prevention and early detection of Diabetes and Hypertension.
Submission deadline: 30th October 2025.
Entries for the above awards can be submitted to us at:
[email protected]
For information on the awards, please visit our website:
www.merck-foundation.com
Click on the link below to Download Merck Foundation App
https://apps.apple.com/co/app/merck-foundation/id1535584997?l=en
Join the conversation on our social media platforms below and let your voice be heard! Facebook: Merck FoundationX: @MerckFoundationYouTube: MerckFoundationInstagram: Merck FoundationThreads: Merck FoundationFlickr: Merck Foundation
Website: https://merck-foundation.com/
The Merck Foundation, established in 2017, is the philanthropic arm of Merck KGaA Germany, aims to improve the health and wellbeing of people and advance their lives through science and technology. Our efforts are primarily focused on improving access to quality & equitable healthcare solutions in underserved communities, building healthcare & scientific research capacity, empowering girls in education and empowering people in STEM (Science, Technology, Engineering, and Mathematics) with a special focus on women and youth. All Merck Foundation press releases are distributed by e-mail at the same time they become available on the Merck Foundation Website. Please visit www.merck-foundation.com to read more. Follow the social media of Merck Foundation: Facebook, X, Instagram, YouTube, Threads and Flickr.
The Merck Foundation is dedicated to improving social and health outcomes for communities in need. While it collaborates with various partners, including governments to achieve its humanitarian goals, the foundation remains strictly neutral in political matters. It does not engage in or support any political activities, elections, or regimes, focusing solely on its mission to elevate humanity and enhance well-being while maintaining a strict non-political stance in all of its endeavors.
Disclaimer: The above press release comes to you under an arrangement with Business Wire. Business Upturn takes no editorial responsibility for the same.
Business Wire is an American company that disseminates full-text press releases from thousands of companies and organizations worldwide to news media, financial markets, disclosure systems, investors, information web sites, databases, bloggers, social networks and other audiences.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Boston Globe
5 hours ago
- Boston Globe
He asked Tiffany Trump to marry him. Then the deals started coming.
Advertisement The second arrangement involved something less tangible: access to the Trumps. Boulos' cousin promised to get a Saudi businessperson invited to the Boulos-Trump wedding so the businessperson could pose for photographs with the Trumps and project a closeness with the family. 'We want you to be at the top of the guest list,' the cousin, Jimmy Frangi, wrote. Get Starting Point A guide through the most important stories of the morning, delivered Monday through Friday. Enter Email Sign Up Everyone involved denies wrongdoing, and both deals went bad. Kushner's yacht sits unfinished in Greece. And the Saudi businessperson never got the access (or the wedding invitation) that he had been offered. But Boulos received about $300,000 from the yacht sale, his cousin says, and $100,000 from the Saudi businessperson. A spokesperson for Boulos and Tiffany Trump said Boulos had received only a prenegotiated finder's fee in the yacht deal and had since ended his business relationship with Frangi, the yacht broker. 'Mr. Boulos is proud of and honored by his close, familial relationship with Mr. Kushner,' the spokesperson said in an email. Advertisement As for the money from the Saudi businessperson, the spokesperson said it had nothing to do with access to the Trumps but was instead to settle an unrelated debt. He said Boulos had no involvement in the plan that his cousin had described in text messages. The Trump administration has blurred the lines between family, business and government, with the president conducting diplomacy with the same foreign governments that are negotiating cryptocurrency and real estate deals with his family. The Bouloses are a variation on that theme. The previously unreported deals — which The New York Times pieced together through contracts, court records, contemporaneous text messages and interviews — show that Boulos, his family and his associates were in a position to benefit financially as soon as he became engaged to Trump, the only child of Donald Trump and his former wife Marla Maples. The wedding, held at the president's Mar-a-Lago golf club in Florida, raised the family's profile and turned the patriarch, Massad Boulos, into an important Trump campaign surrogate. News coverage portrayed him as a billionaire business magnate, even though there is no evidence that he has significant wealth resulting from his own commercial activities. Massad Boulos' stake in his in-laws' Nigerian truck company was worth less than $2, the Times found last year. Trump's election in 2024 propelled Massad Boulos into government. He became a presidential adviser on the Middle East and then a senior State Department adviser on Africa. And Michael Boulos is seeking business there, according to the former prime minister of Guinea. Advertisement 'He is pursuing work,' the former prime minister, Lansana Kouyaté, said in an interview. He would not discuss details but said Boulos told him a few months ago that he was working to 'put together some investors from the United States and some governments in Africa.' Kouyaté said that, as far as he was concerned, the business of Michael Boulos and the political role of his father were inseparable. The former prime minister recounted his conversation with Boulos in two separate interviews. But after Boulos was asked to comment, Kouyaté sent an unsolicited email suddenly denying knowing or speaking with him. Asked to explain the discrepancy, he blamed spotty cell service and said to rely on Boulos' account of the events. He said that someone, whom he would not identify, had told him to email the Times. A spokesperson for Boulos said he did not know Kouyaté and had never spoken to him. Today, Boulos and Tiffany Trump are raising a family. They welcomed their first child, Alexander, in May. Trump has kept a low profile but this week shared photos on Instagram of the family boating and of scenes from the French Riviera. With the Boulos family close to power, associates are also seeking their own opportunities. Around the time of the presidential inauguration, Habib Saidi, a businessperson and close friend of the Bouloses, was sitting with Boulos at Mar-a-Lago when he spotted Kacy Grine, a financier with deep ties in Saudi Arabia, dining on the terrace. Saidi stepped away from Boulos and, in front of others, introduced himself to Grine. Saidi said he and his friends wanted to use the opportunity, while they were close to the center of American power, to do business in the Middle East, according to a person who witnessed the conversation. Saidi mentioned construction projects in Saudi Arabia. Advertisement Saidi said he had no recollection of the conversation. Grine said he would not discuss his business interests. The Superyacht 'Solstice' As a young yacht broker, Boulos had a knack for business development, Frangi recalled. Boulos identified his soon-to-be brother-in-law Jared Kushner as a potential client, and brought Frangi to meet him. The cousins made an investment pitch: Get a good deal on a yacht, refurbish it and sell or lease it as a moneymaker. By June 2021, documents show, Boulos was sending Kushner sales presentations about an unfinished yacht, later named the Solstice. The firm told Kushner that the price to acquire the yacht was about $15 million at the time. That included costs and a flat brokerage commission of 1 million euros for Boulos, Frangi and their colleagues. 'Just so we understand the business deal,' Kushner said on a call, according to portions of a transcript, 'you are going to make 1mm on the closing.' But according to Frangi's text messages at the time, his firm was making much more than that. The brokers were spending millions less to acquire the yacht than they claimed to Kushner, according to Frangi's messages. 'THIS MAKES US 3.5,' Frangi told an associate. The text messages show that his brokerage worked to conceal the details from Kushner. 'It's going to be difficult to hide,' an executive at the firm wrote. He said it was important that Kushner not hire an independent appraiser. Boulos was not copied on those messages, and it is not clear whether he was aware of this aspect of the plan. But text messages make clear that he was personally engaged in the process. When Kushner's lawyer seemed to be slowing the deal down, for example, Boulos made his displeasure known inside the firm. 'Me and Tiffany,' he wrote to associates, are 'pissed off.' Advertisement The family spokesperson said Tiffany Trump had 'no knowledge of or interest in any part of these transactions.' The sale closed in early 2022. Frangi said he had made about $400,000 from the commission, and that Boulos had made $300,000. Frangi also acknowledged taking extra money that had been earmarked for transaction fees. But he said it was a few hundred thousand dollars, not millions. He said that it was wrong to think of the price as inflated. He said the deal called for Kushner's investment group to pay a single sum to buy, transport and insure the yacht. If Frangi could do it all for less, then of course he'd make more profit, he said. If that was the deal, that is not what the contracts say. As for his text messages, Frangi said they were unreliable. 'I write usually very erratic and I just throw things and I always live in the future and everybody knows that about me,' he wrote in a text message to the Times. Kushner eventually realized that he had been overcharged, according to a lawyer who recounted the deal during a client's financial dispute with Frangi. The lawyer, Taylor Howard, wrote that Kushner had been overcharged by $2.5 million and confronted Frangi, who concealed the reason for the higher price. 'In reality, Mr. Frangi was using that to bolster his returns on the transaction,' Howard wrote. Advertisement A spokesperson for Kushner declined to comment on details of the deal. He said Boulos had recently been doing a 'great job' working to find a new buyer for the yacht, and that a deal was pending. The Saudi Deal On June 22, 2022, a few months after the yacht deal closed, Boulos and Frangi gathered at the Virginia home of a wealthy Saudi businessperson. Frangi knew the businessperson, Abdulelah Allam, through the yacht business and was millions of dollars in debt to him. Allam was in Virginia in self-imposed exile. He had potentially billions of dollars in real estate seized by the Saudi government during a 2017 corruption crackdown by Crown Prince Mohammed bin Salman, and was desperate to get his property back. Frangi came up with a plan, text messages show: He could use his relationship with Boulos and the Trump family to help Allam persuade the crown prince to return his property. In exchange, Frangi said, he wanted Allam to forgive his debt and cut him in on a future business deal. Boulos had needs of his own, Frangi said. 'He needs 25,000$,' he told Allam in a text message before the meeting. 'Is loan. I told him.' He included Boulos' name and bank account information. The day of the Virginia meeting, Allam texted that he had deposited $100,000 into Boulos' account. Everyone involved said the money was not intended to buy access. But they offered contradictory explanations for it. According to Boulos' spokesperson, Frangi's 'financially struggling company' owed Boulos money. So, at Frangi's request, the Saudi businessperson settled the debt by paying Boulos himself, the spokesperson said. But an aide to Allam said the money was a loan to Boulos that Boulos still intended to repay. Frangi has explained the money in different ways, at times calling it a loan to Boulos and at other times calling it the settling of a debt. Whatever the purpose, in the weeks and months that followed the $100,000 bank deposit, Frangi detailed plans to 'soften up' Saudi officials. Part of that involved presenting Allam as being close to the Trumps. 'We have a month and a half to get everything started before the wedding,' Frangi wrote in text messages. They strategized about photographs and access. 'Would be good you fly with Michael and Tiffany pls,' he wrote to Allam. Later, in Arabic, he added, 'Please delete all texts.' Boulos was not copied on those text messages. Allam's aide, Rashad el-Hassanieh, said: 'Mikey never promised anything. He said, 'I'll listen, but I can't promise anything.'' Boulos was not involved, his spokesperson said. 'Mr. Boulos has never dealt with, been involved with, nor discussed Mr. Allam's Saudi Arabia concerns with anyone, including Mr. Allam himself,' he said. As months went on, people around Allam warned him that the plan had little chance of working, messages show. They were right. Allam never got his wedding invite, his access or his property back. This article originally appeared in
Yahoo
15 hours ago
- Yahoo
New NHS bladder cancer treatment doubles survival time
The NHS will roll out a new treatment for advanced bladder cancer which doubles survival time. It's estimated that 1,250 people a year could benefit from a combination of drugs called enfortumab vedotin and pembrolizumab. The first is an antibody-drug also known as Padcev, made by Astellas and Pfizer, while the latter is a PD-L1 inhibitor, also known as Keytruda, which is made by Merck. Clinical trials suggest the combo leads to improved survival compared to platinum-based chemotherapy - increasing from an average of around 16 months to almost 34. Researchers also found people survive for longer without their disease worsening, also known as progression-free survival - going up from six months to more than a year. It will mark the first significant change to treatment of advanced bladder cancer since the 1980s, according to expert Professor Thomas Powels, director of Barts Cancer Institute Biomedical Research Centre (QMUL). Around 18,000 people in England are diagnosed with bladder cancer each year. Read more from Sky News: The new treatment was approved for NHS use by the National Institute for Health and Care Excellence, which said it was "highly promising" and could make a "tremendous difference" to people. One patient who took part in the trial said it had given him more time with his grandson. Martyn Hewett, 75, from Stratford, east London, said: "I feel very, very lucky, because if I hadn't been on this trial, I imagine I would be dead by now. "I am going to have an extra few years to see my grandson grow up - and maybe even be around to see him get married."
Yahoo
18 hours ago
- Yahoo
Merck (MRK) Announces Positive Phase 3 Trial Results For KEYTRUDA In Bladder Cancer Treatment
Merck recently announced positive topline results from its Phase 3 KEYNOTE-905 trial, showcasing efficacy for KEYTRUDA in patients with muscle-invasive bladder cancer, which adds substantial promise to their oncology pipeline. Over the last quarter, Merck's shares increased by 4.44%, aligning with the broader market's upward trend, exemplified by the S&P 500 and Nasdaq Composite hitting all-time highs. While the company's advancements in KEYTRUDA applications and Health Canada's approval for cervical cancer treatment enhancement could have contributed positively, general market optimism associated with recent stability in inflation and expected Federal Reserve interest rate cuts likely added further weight. We've identified 1 possible red flag for Merck that you should be aware of. Uncover 14 companies that survived and thrived after COVID and have the right ingredients to survive Trump's tariffs. The recent positive topline results from Merck's Phase 3 KEYNOTE-905 trial could enhance the narrative around its strategic investments and new product launches. These developments may bolster Merck's leadership in oncology, potentially driving future revenue as KEYTRUDA applications expand. The efficacy in muscle-invasive bladder cancer strengthens their oncology pipeline, possibly counterbalancing challenges such as declining GARDASIL sales and looming KEYTRUDA exclusivity loss. Over a longer five-year period, Merck's total shareholder return, including dividends, increased by 15.68%, providing broader context compared to its recent quarterly performance. However, over the past year, Merck underperformed the US market, which returned 19.4%, highlighting potential areas for growth despite the positive trial results. The promising trial outcomes may positively impact revenue and earnings forecasts, aligning with analysts' assumptions of a 4.3% annual revenue growth over the next three years. If expectations hold, earnings might reach US$24.3 billion by 2028. Such advancements in the oncology segment could be pivotal given the price target of US$100.41. With the current share price at US$80.03, the price target implies a potential increase of 25.5%, assuming other market conditions remain constant. Evaluate Merck's prospects by accessing our earnings growth report. This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned. Companies discussed in this article include MRK. This article was originally published by Simply Wall St. Have feedback on this article? Concerned about the content? with us directly. Alternatively, email editorial-team@ Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
